Pearl River Capital’s Atara Biotherapeutics ATRA Stock Holding History

Pearl River Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4	Closed	-$3K	–	374
2018 Q4	$3K	Buy	+4	New	+$3.71K	0.01%	757

Other funds holding ATRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pearl River Capital's ATRA Position: Q1 2019 in Review

Pearl River Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2019, closing a stake of 4 shares — an estimated $3K sold.

Pearl River Capital first reported a position in ATRA in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 120 funds tracked by Wall St. Rank hold ATRA as of Q1 2019.

Pearl River Capital reported no remaining Atara Biotherapeutics position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 4 Atara Biotherapeutics shares in Q1 2019, an estimated $3K.
Pearl River Capital first reported a position in Atara Biotherapeutics in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Atara Biotherapeutics position peaked at $3K in Q4 2018.
120 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.